What are the benefits and risks of being in this study?

One benefit of taking part in this study is that your health will be monitored frequently. However, there is no guarantee that this study will improve your health. It may stay the same or it may get worse. Also, as with all drugs, the study drugs may cause side effects. We may be able to prevent or manage some of these and many go away quickly. Any study has risks, which may include things that could make you feel sick or uncomfortable or could cause harm. The study staff will review potential risks before study enrollment.

Can I decide not to be in the study?

Taking part in a clinical study is voluntary. If you are eligible to enroll, you may choose to join the study but leave at a later date for any reason at any time. Regardless of whether you choose to enroll or leave the study early, your future healthcare won’t be affected.

How can I learn more about this study?

To learn more please visit www.gskdestinystudy.com or scan the code below.

NOW ENROLLING:

The DESTINY Study

for adults with uncontrolled hypereosinophilic syndrome (HES)

A quick reference guide for potential participants in the DESTINY study

Thank you for your interest in the DESTINY study. This fact sheet provides more details about the study so you can decide if you want to find out more information. If you have questions or would like to know more, please visit www.gskdestinystudy.com or scan the code on the back cover.
Why is this study important?
HES is a rare, underdiagnosed condition that occurs when you have high numbers of eosinophils. Eosinophils are white blood cells that play an important role in your immune system. Inflammatory tissue damage and dysfunction can occur when eosinophils are overproduced for prolonged periods of time.
People living with HES are in need of more effective therapies for this condition. The purpose of this study is to evaluate the safety and effectiveness of an investigational drug (depemokimab) administered every 6 months compared to a placebo administered every 6 months.

How are the study drugs being tested?
In this study, you will be assigned to a study drug group. You will receive either:
• An investigational drug (depemokimab) given as injections every 6 months (in addition to your standard HES therapy as prescribed by your doctor)
OR
• A placebo drug given as injections every 6 months (in addition to your standard HES therapy as prescribed by your doctor)
You will not be told which group you are in.

How long will I be in this study?
After the screening visit, you will receive two injections every 6 months. This study will consist of at least 18 visits (in-clinic or remotely) over a period of up to 56 weeks plus a follow-up phone call 4 weeks after the final visit (additional visits may be necessary for HES flares).